PureTech Health Announces Change in Voting Rights Attribution

PureTech Health ( (GB:PRTC) ) just unveiled an announcement.

PureTech Health PLC has announced a change in the nature of attribution due to a reduction in the Right to Recall securities, following an acquisition or disposal of voting rights and financial instruments by Citigroup Inc. This adjustment has resulted in Citigroup holding a total of 5.410498% of voting rights in PureTech, indicating a slight increase from the previous position, which may impact the company’s shareholder dynamics and influence.

The most recent analyst rating on (GB:PRTC) stock is a Buy with a £455.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.

Spark’s Take on GB:PRTC Stock

According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.

PureTech Health’s overall stock score reflects strong earnings call insights and promising valuation metrics. While its financial performance shows some liquidity strength, operational risks and inconsistent profitability are concerns. Technical indicators suggest potential short-term positivity.

To see Spark’s full report on GB:PRTC stock, click here.

More about PureTech Health

PureTech Health PLC is a UK-based company operating in the healthcare sector, focusing on developing innovative therapies and technologies to address significant unmet medical needs. The company is engaged in the discovery and development of novel therapeutics that target the brain, immune, and gut systems.

Average Trading Volume: 677,991

Technical Sentiment Signal: Sell

Current Market Cap: £326.7M

Find detailed analytics on PRTC stock on TipRanks’ Stock Analysis page.